Tamper-resistant oxycodone tablets have no impact on overall opioid use

January 11, 2018, University of New South Wales
Tamper-resistant oxycodone tablets have no impact on overall opioid use
Credit: Shutterstock

The introduction of tamper-resistant opioid tablets does not have an effect on rates of opioid use or harms at a population level, according to a new study led by the National Drug and Alcohol Research Centre (NDARC) at UNSW Sydney.

A tamper-resistant, difficult to crush formulation of OxyContin, a strong opioid prescribed for chronic pain management, was introduced in Australia in April 2014 in response to growing concerns about its contribution to an increase in opioid use and related harms.

The National Opioid Medications Abuse Deterrence (NOMAD) study – the most comprehensive analysis of the impact of tamper-resistant opioid formulations to date – is published in The Lancet Psychiatry journal.

The study used both sales and health data across Australia, as well as survey data from a cohort of 600 people who misuse pharmaceutical opioids, to measure the new formulation's impact on opioid use and opioid-related harm as well as opioid use and tampering among high-risk populations.

While the study found that people who inject drugs were less likely to tamper with the tablets, the lack of any significant effect on opioid use or harms highlights the need for a multifaceted approach to opioid overuse.

"Although the introduction of this tamper-resistant formulation resulted in less use of that particular opioid among people who inject drugs, its introduction must be considered as part of a multifaceted response," says NDARC's Dr. Briony Larance.

"This includes increasing the availability of non-medication approaches to chronic pain, good clinical practice in long-term opioid treatment, and harm reduction among people who use opioids outside the recommendations of their prescriber.

"Approximately 2.9 million Australians were prescribed an opioid in 2014, compared with an estimated 93,000 people who injected drugs. As a population-wide strategy to reduce harm of overuse or overprescription of opioids, the introduction of tamper-resistant formulations alone will not be sufficient to affect these outcomes," she says.

The in the USA is widely documented and similar problems in Australia are emerging, with opioid use in 2012 15 times that reported in 1992. Pharmaceutical opioids cause more than 70% of opioid overdose deaths in Australia – similar rates to the USA.

In the USA, oxycodone was developed in a tamper-resistant formulation, making it harder to crush or dissolve the tablets. Early studies suggested the tamper-resistant formulations were associated with reduced recreational use, poisonings and sales, and increased heroin use and harm.

The NOMAD study analysed a total of 17 data sources including opioid sales data, multiple health datasets, annual surveys of people who inject drugs, and a cohort of 606 people who reported tampering with opioids before and after the introduction of tamper-resistant tablets. Data from three Australian states – New South Wales, South Australia and Tasmania – were included in the study.

The introduction of tamper-resistant oxycodone was associated with a reduction in use among the cohort of people who reported tampering with the tablets to inject opioids, and there was no evidence that this cohort of people switched to other opioids.

At a population level, the introduction of tamper-resistant oxycodone was associated with reduced sales of higher strength controlled-release oxycodone, but increased sales of lower strength oxycodone formulations. Additionally, there was almost no effect on the introduction of the tamper-resistant tablets at the population level. Opioid use continued to increase at a similar rate before and after the introduction of tamper-resistant tablets.

There was no effect (positive or negative) on any population-level rates of harms, such as hospital admissions, emergency department presentations or ambulance overdoses.

The authors note that some of the datasets lacked specificity about which type of opioid was being used, which may have affected the results, but point to the strength of the study which lies in the use of multiple datasets.

In a separate editorial published in the same journal, Dr. Nabarun Dasgupta of University of North Carolina writes: "The NOMAD study provides the most complete and compelling evaluation of replacing a CR analgesic with a tamper resistant formulation of controlled release oxycodone."

Explore further: Tamper-resistant opioids will not solve opioid addiction problem

More information: Briony Larance et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study, The Lancet Psychiatry (2018). DOI: 10.1016/S2215-0366(18)30003-8

Related Stories

Tamper-resistant opioids will not solve opioid addiction problem

June 29, 2015
Tamper-resistant formulations of drugs will not solve the problems of opioid addiction and overdose, argues a commentary in CMAJ (Canadian Medical Association Journal).

Gabapentin co-use may increase risk of fatal opioid overdose

October 3, 2017
Co-prescription of the anticonvulsant gabapentin is associated with an increased risk of opioid-related death in people who are prescribed opioid painkillers, according to a new study published in PLOS Medicine.

CDC launches opioid campaign in hard-hit states

September 26, 2017
(HealthDay)—The U. S. Centers for Disease Control and Prevention has launched a campaign to reduce overdose deaths from prescription opioid painkillers.

Bulk of opioid use in the U.S. concentrated among 10 percent of patients

September 11, 2017
A small proportion (10 percent) of opioid users account for the vast majority of opioid use in the United States. These findings suggest that efforts to reduce prescription opioid abuse should focus on the top users, rather ...

Strategies to combat the opioid epidemic

November 15, 2017
The opioid epidemic is ravaging lives and tearing families apart. Overdose deaths from heroin, fentanyl and misused prescription painkillers have tripled in the past 15 years. Chemical & Engineering News, the weekly newsmagazine ...

More Australians dying of accidental overdose of pharmaceutical opioids

July 24, 2017
In a reversal of the heroin epidemic of the late 90s and early 2000s, older Australians aged 35 to 54 are now more likely to die from an opioid overdose, a new report reveals.

Recommended for you

Study shows how bias can influence people estimating the ages of other people

October 17, 2018
A trio of researchers from the University of New South Wales and Western Sydney University has discovered some of the factors involved when people make errors in estimating the ages of other people. In their paper published ...

Infants are more likely to learn when with a peer

October 16, 2018
Infants are more likely to learn from on-screen instruction when paired with another infant as opposed to viewing the lesson alone, according to a new study.

Researchers use brain cells in a dish to study genetic origins of schizophrenia

October 16, 2018
A study in Biological Psychiatry has established a new analytical method for investigating the complex genetic origins of mental illnesses using brain cells that are grown in a dish from human embryonic stem cells. Researchers ...

Income and wealth affect the mental health of Australians, study shows

October 16, 2018
Australians who have higher incomes and greater wealth are more likely to experience better mental health throughout their lives, new research led by the Bankwest Curtin Economics Centre has found.

Linguistic red flags from Facebook posts can predict future depression diagnoses

October 15, 2018
In any given year, depression affects more than 6 percent of the adult population in the United States—some 16 million people—but fewer than half receive the treatment they need. What if an algorithm could scan social ...

Early changes to synapse gene regulation may cause Alzheimer's disease

October 15, 2018
Alzheimer's disease (AD) is the most common form of dementia, involving memory loss and a reduction in cognitive abilities. Patients with AD develop multiple abnormal protein structures in their brains that are thought to ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.